These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30963282)

  • 1. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?
    Mauras M; Bacchetta J; Duncan A; Lavocat MP; Rohmer B; Javouhey E; Collardeau-Frachon S; Sellier-Leclerc AL
    Pediatr Nephrol; 2019 Jul; 34(7):1289-1293. PubMed ID: 30963282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.
    de Zwart PL; Mueller TF; Spartà G; Luyckx VA
    Pediatr Nephrol; 2024 May; 39(5):1369-1385. PubMed ID: 38057431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
    Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
    Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.
    Delmas Y; Vendrely B; Clouzeau B; Bachir H; Bui HN; Lacraz A; Hélou S; Bordes C; Reffet A; Llanas B; Skopinski S; Rolland P; Gruson D; Combe C
    Nephrol Dial Transplant; 2014 Mar; 29(3):565-72. PubMed ID: 24293658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.
    Pape L; Hartmann H; Bange FC; Suerbaum S; Bueltmann E; Ahlenstiel-Grunow T
    Medicine (Baltimore); 2015 Jun; 94(24):e1000. PubMed ID: 26091445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
    Garnier A; Brochard K; Kwon T; Sellier-Leclerc AL; Lahoche A; Launay EA; Nobili F; Caillez M; Taque S; Harambat J; Michel-Bourdat G; Guigonis V; Fila M; Cloarec S; Djamal-Dine D; de Parscaux L; Allard L; Salomon R; Ulinski T; Frémeaux-Bacchi V; Morin C; Olivier-Abbal P; Colineaux H; Auriol F; Arnaud C; Kieffer I; Brusq C
    J Am Soc Nephrol; 2023 Sep; 34(9):1561-1573. PubMed ID: 37303085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.
    Galvez C; Krall P; Rojas A; Oh J; Cano F
    Pediatr Nephrol; 2023 Apr; 38(4):1195-1203. PubMed ID: 35969277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M
    Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ockham's razor defeated: about two atypical cases of hemolytic uremic syndrome.
    Schwarz C; Brehon A; Mousseaux C; Luque Y; Senet P; Mariani P; Mohamadou I; Zafrani L; Frémeaux-Bacchi V; Rondeau E; Buob D; Rafat C
    BMC Nephrol; 2020 Jul; 21(1):269. PubMed ID: 32652955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic uremic syndrome in children.
    Talarico V; Aloe M; Monzani A; Miniero R; Bona G
    Minerva Pediatr; 2016 Dec; 68(6):441-455. PubMed ID: 27768015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab in severe Shiga-toxin-associated HUS.
    Lapeyraque AL; Malina M; Fremeaux-Bacchi V; Boppel T; Kirschfink M; Oualha M; Proulx F; Clermont MJ; Le Deist F; Niaudet P; Schaefer F
    N Engl J Med; 2011 Jun; 364(26):2561-3. PubMed ID: 21612462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.